Repligen Corporation to Present at Upcoming May Investor Conferences

Rhea-AI Summary

Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in two major investor conferences in May 2025. The company's Chief Financial Officer, Jason K. Garland, will represent Repligen at:

1. RBC Capital Markets' 2025 Global Healthcare Conference in New York (May 20-21), featuring an analyst-led discussion on May 20 at 3:35 p.m. ET

2. Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis (May 28)

Both events will include one-on-one meetings with investors. The RBC conference presentation will be available via live webcast on Repligen's Investor Relations website.

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

• RBC Capital Markets’ 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.
• Craig-Hallum’s 22^nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series of one-on-one meetings with investors.

A live webcast of the RBC conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com

FAQ

When is Repligen (RGEN) presenting at the RBC Capital Markets Healthcare Conference 2025?

Repligen's CFO Jason K. Garland will present at the RBC Capital Markets Healthcare Conference on May 20, 2025, at 3:35 p.m. ET in New York.

How can I watch Repligen's (RGEN) presentation at the RBC Healthcare Conference?

The presentation can be watched via live webcast through Repligen's Investor Relations website at www.repligen.com, with replay available for a limited time after the event.

Which conferences will Repligen (RGEN) attend in May 2025?

Repligen will attend the RBC Capital Markets' Global Healthcare Conference in New York (May 20-21) and Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis (May 28).

Who will represent Repligen (RGEN) at the May 2025 investor conferences?

Jason K. Garland, Repligen's Chief Financial Officer, will represent the company at both investor conferences.